Jiangsu Hengrui Medicine Co., Ltd. announced a private placement for gross proceeds of $533,000,000 on May 18, 2025. The transaction includes participation from returning investors, GIC Private Limited, Oaktree Capital Management, L.P. and Hillhouse Investment Management, Ltd. and from new investors, Invesco Ltd., UBS Group AG, Boyu Capital Group Management Ltd. and Millennium Point.